Process for the preparation of optically active (S)-(−)-2-(N-propylamino)-5-methoxytetraline and (S)-(−)-2-(N-propylamino)-5-hydroxytetraline compounds
    1.
    发明授权
    Process for the preparation of optically active (S)-(−)-2-(N-propylamino)-5-methoxytetraline and (S)-(−)-2-(N-propylamino)-5-hydroxytetraline compounds 有权
    制备光学活性(S) - ( - ) - 2-(N-丙基氨基)-5-甲氧基四氢化萘和(S) - ( - ) - 2-(N-丙基氨基)-5-羟基四氢化萘化合物的方法

    公开(公告)号:US08604242B2

    公开(公告)日:2013-12-10

    申请号:US13059650

    申请日:2009-10-09

    IPC分类号: C07B57/00 C07C211/00

    摘要: The present invention describes a novel process for the preparation of optically active (S)-(−)-2-(N-propylamino)-5-methoxytetraline and (S)-(−)-2-(N-propylamino)-5-hydroxytetraline compounds based on the optical resolution of mixtures of the enantiomers of 2-(N-propylamino)-5-methoxytetraline and 2-(N-propylamino)-5-hydroxytetraline respectively. This process comprises (a) reacting a mixture of the enantiomers of said compounds with an optically active organic acid to form diastereoisomeric salts and separating the salts by crystallization. Said compounds are useful in the preparation of (6S)-(−)-5,6,7,8-tetrahydro-6-[propyl-(2-thienyl)ethyl]amino-1-naphthol (Rotigotine). Rotigotine is a dopamine agonist and is indicated for the treatment of Parkinson's disease.

    摘要翻译: 本发明描述了制备光学活性(S) - ( - ) - 2-(N-丙基氨基)-5-甲氧基四氢化萘和(S) - ( - ) - 2-(N-丙基氨基)-5 基于2-(N-丙基氨基)-5-甲氧基四氢化萘和2-(N-丙基氨基)-5-羟基四氢化萘的对映异构体的混合物的光学拆分的羟基四氢化萘化合物。 该方法包括(a)使所述化合物的对映异构体与光学活性有机酸的混合物反应以形成非对映异构体盐,并通过结晶分离盐。 所述化合物可用于制备(6S) - ( - ) - 5,6,7,8-四氢-6- [丙基 - (2-噻吩基)乙基]氨基-1-萘酚(罗替戈汀)。 罗替戈汀是一种多巴胺激动剂,用于治疗帕金森病。

    PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS
    2.
    发明申请
    PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS 有权
    制备光学活性(S) - ( - ) - 2-(N-丙基氨基)-5-甲氧基 - 和 - ( - ) - ( - ) - 2-(N-丙基氨基)-5-羟基化合物的方法

    公开(公告)号:US20110152543A1

    公开(公告)日:2011-06-23

    申请号:US13059650

    申请日:2009-10-09

    摘要: The present invention describes a novel process for the preparation of optically active (S)-(−)-2-(N-propylamino)-5-methoxytetraline and (S)-(−)-2-(N-propylamino)-5-hydroxytetraline compounds based on the optical resolution of mixtures of the enantiomers of 2-(N-propylamino)-5-methoxytetraline and 2-(N-propylamino)-5-hydroxytetraline respectively. This process comprises (a) reacting a mixture of the enantiomers of said compounds with an optically active organic acid to form diastereoisomeric salts and separating the salts by crystallization. Said compounds are useful in the preparation of (6S)-(−)-5,6,7,8-tetrahydro-6-[propyl-(2-thienyl)ethyl]amino-1-naphthol (Rotigotine). Rotigotine is a dopamine agonist and is indicated for the treatment of Parkinson's disease.

    摘要翻译: 本发明描述了一种制备光学活性(S) - ( - ) - 2-(N-丙基氨基)-5-甲氧基四氢化萘和(S) - ( - ) - 2-(N-丙基氨基)-5 基于2-(N-丙基氨基)-5-甲氧基四氢化萘和2-(N-丙基氨基)-5-羟基四氢化萘的对映异构体的混合物的光学拆分的羟基四氢化萘化合物。 该方法包括(a)使所述化合物的对映异构体与光学活性有机酸的混合物反应以形成非对映异构体盐,并通过结晶分离盐。 所述化合物可用于制备(6S) - ( - ) - 5,6,7,8-四氢-6- [丙基 - (2-噻吩基)乙基]氨基-1-萘酚(罗替戈汀)。 罗替戈汀是一种多巴胺激动剂,用于治疗帕金森病。